Company
Every investor coverage indicates participated in a round Wellcome raised.
Companies Wellcome acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Wellcome. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.
Brisbane vaccine patch maker Vaxxas won a $5.4 million Wellcome grant for studies and a Phase I trial of a typhoid vaccine using its HD-MAP technology, developed with SK bioscience.